Matsuzawa and collaborators also showed that MSLN blockade by Amatuximab increases c-met expression, another CSC marker, in pancreatic cancer cell lines, suggesting an indirect link between MSLN and the CSC phenotype [32]. Here, MET is linked to familial pancreatic carcinoma.